Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03850782




Registration number
NCT03850782
Ethics application status
Date submitted
11/02/2019
Date registered
22/02/2019

Titles & IDs
Public title
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
Scientific title
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
Secondary ID [1] 0 0
2018-002574-52
Secondary ID [2] 0 0
1698-301-007
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Open-Angle Glaucoma 0 0
Ocular Hypertension 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Bimatoprost (SR)

Experimental: Bimatoprost SR - Dose A - Study Eye: Participants will receive 1 - 2 Cycles of Bimatoprost SR administrations of Dose A

Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR.

Experimental: Bimatoprost SR - Dose B - Study Eye: Participants received 1 - 3 Cycles of Bimatoprost SR administrations of Dose B

Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR.


Treatment: Drugs: Bimatoprost (SR)
Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.

Fellow Eye: Standard of care or Bimatoprost SR.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Retreatment or rescue administered for IOP
Timepoint [1] 0 0
Up to 48 months
Primary outcome [2] 0 0
Number of patients experiencing a treatment emergent adverse event
Timepoint [2] 0 0
Baseline up to 48 months

Eligibility
Key inclusion criteria
- Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Concurrent or anticipated enrollment in another investigational drug or device study or participation in such a study within 2 months prior to enrolling in this study.
* Previous administration with Bimatoprost SR in the study eye.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/02/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
9/08/2025
Actual
Sample size
Target
Accrual to date
Final
515
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Eye Surgery Associates /ID# 235873 - East Melbourne
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
South Dakota
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Utah
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
Argentina
State/province [21] 0 0
Buenos Aires
Country [22] 0 0
Argentina
State/province [22] 0 0
Santa Fe
Country [23] 0 0
Argentina
State/province [23] 0 0
Ciudad Autonoma Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Ciudad de Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Mendoza
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Sofia
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Burgas
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Plovdiv
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Sliven
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Smolyan
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Stara Zagora
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Varna
Country [33] 0 0
Czechia
State/province [33] 0 0
Pardubice
Country [34] 0 0
Czechia
State/province [34] 0 0
Praha
Country [35] 0 0
Denmark
State/province [35] 0 0
Hovedstaden
Country [36] 0 0
Germany
State/province [36] 0 0
Baden-Wuerttemberg
Country [37] 0 0
Germany
State/province [37] 0 0
Schleswig-Holstein
Country [38] 0 0
Germany
State/province [38] 0 0
Dresden
Country [39] 0 0
Germany
State/province [39] 0 0
Goettingen
Country [40] 0 0
Germany
State/province [40] 0 0
Hamburg
Country [41] 0 0
Germany
State/province [41] 0 0
Muenster
Country [42] 0 0
Germany
State/province [42] 0 0
Neubrandenburg
Country [43] 0 0
Germany
State/province [43] 0 0
Rostock
Country [44] 0 0
Germany
State/province [44] 0 0
Starnberg
Country [45] 0 0
Hungary
State/province [45] 0 0
Heves
Country [46] 0 0
Hungary
State/province [46] 0 0
Vas
Country [47] 0 0
Hungary
State/province [47] 0 0
Budapest
Country [48] 0 0
Ireland
State/province [48] 0 0
Dublin
Country [49] 0 0
Ireland
State/province [49] 0 0
Waterford
Country [50] 0 0
Italy
State/province [50] 0 0
Calabria
Country [51] 0 0
Italy
State/province [51] 0 0
Catania
Country [52] 0 0
Italy
State/province [52] 0 0
Chieti
Country [53] 0 0
Italy
State/province [53] 0 0
Pavia
Country [54] 0 0
Italy
State/province [54] 0 0
Perugia
Country [55] 0 0
Italy
State/province [55] 0 0
Rome
Country [56] 0 0
Italy
State/province [56] 0 0
Terracina
Country [57] 0 0
New Zealand
State/province [57] 0 0
Canterbury
Country [58] 0 0
New Zealand
State/province [58] 0 0
Wellington
Country [59] 0 0
Poland
State/province [59] 0 0
Mazowieckie
Country [60] 0 0
Poland
State/province [60] 0 0
Pomorskie
Country [61] 0 0
Poland
State/province [61] 0 0
Katowice
Country [62] 0 0
Poland
State/province [62] 0 0
Lodz
Country [63] 0 0
Poland
State/province [63] 0 0
Olsztyn
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Novosibirsk
Country [65] 0 0
South Africa
State/province [65] 0 0
Gauteng
Country [66] 0 0
South Africa
State/province [66] 0 0
Western Cape
Country [67] 0 0
Sweden
State/province [67] 0 0
Vasterbottens Lan
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Essex
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Oxfordshire
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Cambridge
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Chelmsford
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Colchester
Country [73] 0 0
United Kingdom
State/province [73] 0 0
Crewe
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Liverpool
Country [75] 0 0
United Kingdom
State/province [75] 0 0
London
Country [76] 0 0
United Kingdom
State/province [76] 0 0
York

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
When will data be available (start and end dates)?
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Available to whom?
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://vivli.org/ourmember/abbvie/


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03850782